The EMA's CHMP recommended approval of daraxonrasib for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.
Quiz|Articles|October 16, 2026
OncLive Weekly News Quiz (10/16/2026): Did You Miss Crucial Bladder, Neuroendocrine, Pancreatic, and Liver Cancer Updates?
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Advertisement
The FDA approved nogapendekin alfa inbakicept-pmln (Anktiva) plus BCG in a new bladder cancer setting, supported by cohort B of the phase 2/3 QUILT-3.032 trial (NCT03022825). Which population does this expanded indication cover?
Advertisement
Related to this article
VS-7375 produced a responses previously treated metastatic pancreatic ductal adenocarcinoma.
The resubmission follows a third complete response letter issued in July 2026 that cited manufacturing deficiencies rather than efficacy or safety concerns.
The FDA approved nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with high-grade papillary-only tumors.
The FDA granted fast track designation to opamtistomig for first-line treatment of advanced or metastatic biliary tract cancer.
A planned interim analysis of the radiopharmaceutical RYZ101 showed improved PFS by blinded independent central review vs standard of care.
The top 5 OncLive TV videos of the week.
Check out this September recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.
Advertisement
Advertisement
Trending on OncLive
1
CHMP Recommends Approval of Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer
2
Stay Ahead of ESMO 2026: See What Lung Cancer Experts Are Prioritizing
3
Lifileucel Linked to Low Rates of Post-Discharge Severe TRAEs, Readmissions in Advanced Melanoma
4
Refined ADC Development Helps Weigh Biomarker-Based Decisions and Treatment Sequencing in Gynecologic Cancers
5